Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Kymab Limited
- Target Recruit Count
- 390
- Registration Number
- NCT05131477
- Locations
- 🇺🇸
Investigative Site Number: 1007, Miami, Florida, United States
🇵🇱Investigative site #2420, Łódź, Poland
🇺🇸Investigative Site Number: 1014, Beverly, Massachusetts, United States
A Study of Subcutaneous KY1005 in Healthy Volunteers
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Kymab Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04449939
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1
Terminated
- Conditions
- Squamous Cell Carcinoma of Head and NeckNon-small Cell Lung CancerHepatocellular CarcinomaEsophageal CancerGastric CancerMelanomaRenal Cell CarcinomaPancreatic CancerCervical CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Kymab Limited
- Target Recruit Count
- 222
- Registration Number
- NCT03829501
- Locations
- 🇮🇹
Kymab investigational site 3904, Meldola, Forlì-Cesena, Italy
🇺🇸Kymab investigational site 1103, Nashville, Tennessee, United States
🇺🇸Kymab investigator site 1101, Houston, Texas, United States
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Kymab Limited
- Target Recruit Count
- 89
- Registration Number
- NCT03754309
- Locations
- 🇩🇪
Kymab investigational site 106, Kiel, Germany
🇩🇪Kymab investigational site 113, Leipzig, Germany
🇵🇱Kymab investigational site 207, Gdansk, Poland
A Study of KY1005 in Healthy Volunteers
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Kymab Limited
- Target Recruit Count
- 64
- Registration Number
- NCT03161288
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
© Copyright 2025. All Rights Reserved by MedPath